December 19, 2019 / 6:09 AM / a month ago

BRIEF-EU approves Roche's Kadcyla in early breast cancer

Dec 19 (Reuters) - Roche Holding AG:

* EUROPEAN COMMISSION APPROVES ROCHE’S KADCYLA FOR THE ADJUVANT TREATMENT OF PEOPLE WITH HER2-POSITIVE EARLY BREAST CANCER WITH RESIDUAL INVASIVE DISEASE AFTER NEOADJUVANT TREATMENT Further company coverage: (Reporting by Silke Koltrowitz)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below